Myodil Sufferer Derek Morrison Brings Vigil To Washington..


…“This dye was used in 107 countries. I believe 186,000 people were injected with Pantopaque in Australia, more when you take into account Myodil,” he says…

https://www.dailytelegraph.com.au/lifestyle/health/derek-morrison-tells-of-how-the-toxic-xray-dye-affected-him-and-prompted-his-pursuit-for-justice/news-story/6242b2c54637e125886562801cf1c2fb

 

GSK’s Myodil scandal is horrific..

Please see Derek Morrison and his brilliant expose on GSK’s horrific X Ray dye..

Do you think Emma Walmsley, Andrew Witty or Patrick Vallance (GSK executives) give a damn about people like Derek?

Or do they give a damn about those dead from Seroxat or Avandia (other GSK drugs)…

I doubt it, because if they did they would do something!

Yet they don’t.. they just continue to pick up their GSK pay checks. Their GSK stocks and shares will make sure that they live a life of luxury while people like Derek’s lives are destroyed and ruined…

 


 

This is bigger than tobacco or asbestos.” On August 25th, 2017, chemically induced Adhesive Arachnoiditis (CIAA) sufferer Derek Morrison traveled alone from his home in Australia to set up a vigil in front of the White House, where he presented his disturbing findings from 25 years of historical medical research into the main cause of CIAA: an FDA-approved x-ray dye that was developed and tested under questionable regulatory procedures and then distributed, marketed, and used by doctors for decades on millions of x-ray patients who were never informed of the risk. This video is intended to raise awareness of CIAA and to invite public and official review of Derek’s research findings, which can be found at the following website: https://pantopaque.wordpress.com Please share this video! If just one person can learn about the source of their physical pain from watching this video, then you’ll have made a difference in the world. Thank you!!

Advertisements

Glaxo In Court Again… This Time Over Myodil…


Myodil is a truly scandalous and horrific GSK product…


http://www.lexology.com/library/detail.aspx?g=676e9823-1d6b-4912-b733-d5e8b10c088d

Date of knowledge and Limitation – Lewin v Glaxo – Case Report
Blog piBlawg

United Kingdom January 18 2017

In cases concerning an allegation of bodily injury, time for the purposes of statutory limitation does not begin to run until the cause of action accrues or the date of knowledge of the alleged victim. The latter may be some months or years after the effluxion of the usual three year limitation period from the accrual of the cause of action. However it is rarely decades as it was in a recent case in the Queen’s Bench Division. In common with much of the extensive corpus of authority as to limitation, Keith Malcolm Lewin v Glaxo Operations Uk Ltd (Sued As Glaxosmithkline Unltd) [2016] EWHC 3331 (QB), turns on its own facts. It is however worthy of summary.

Here, upon hearing the trial of a preliminary issue on the subject, Mr Justice Goss found that the claimant’s claim was not statute-barred despite the claimant making complaint of treatment he received as long ago as 1973.

Some 44 years ago, the claimant underwent a diagnostic procedure during which Mydil was injected into his spine. It was held that the claimant’s date of knowledge arose when he was diagnosed as late as 2015 as suffering from post-Myodil adhesive arachnoiditis.

In the five or so years following the 1973 procedure, the claimant experienced persisting problems in his lumbar and cervical spine. This was investigated further in 1977 when it was considered that whilst the claimant may have had adhesive arachnoiditis, it could not be confirmed and further x-rays were unnecessary. The claimant’s problems continued during the 1990s, but it was not until 2007 when he developed severe left knee pain and thereafter other symptoms. An MRI scan in 20112 showed adhesions to his thoracic spine and the potential link between Myodil and the claimant’s condition was discussed. He underwent surgery in 2013, but it was not until March 2015 when a neurosurgeon concluded that the claimant suffered from post-Myodil adhesive arachnoiditis.

The claimant issued proceedings in October 2015 against the background of the fact that in the early 1990s group litigation had been pursued against the defendant in respect of Myodil in which settlements were agreed without any admission of liability. Over 4000 individuals had notified claims although, in the event, only 426 claims were proceeded with.

The Court was asked to determine the date upon which the claimant’s cause of action accrued; his knowledge for the purposes of section 14 of the Limitation Act 1980; and if the claim was statute-barred, whether the court’s discretion pursuant to section 33 of the same Act should be applied.

The court held that the cause of action accrued when the Myodil caused injury to the claimant, not the date it was injected. On the facts of this case this occurred around 2007.

The defendant argued that by the 1980s the claimant had constructive knowledge sufficient to commence time running (per section 14(3) of the 1980 Act): he knew by 1977 he had a serious back injury and that the possibility of arachnoidiis had been raised sufficient to prompt him to investigate. The claimant argued that no clear cause for his symptoms had been determined. This found favour with the Court which further held that even had the claimant drawn a link, it was not reasonable to have expected him to have investigated it further. It was held therefore that the claimant’s date of knowledge was when the neurosurgeon’s diagnosis in 2015.

Goss J went on to consider whether he would have allowed an extension of limitation in any event. He held that he would have done had it have been necessary on the grounds that the claimant had sustained a very serious injury and the main prejudice to the defendant would have been financial as the matters complained of had already been investigated.

Myodil: Lewin Vs Glaxo..


Date of knowledge and Limitation – Lewin v Glaxo – Case Report
Blog piBlawg

United Kingdom January 18 2017

In cases concerning an allegation of bodily injury, time for the purposes of statutory limitation does not begin to run until the cause of action accrues or the date of knowledge of the alleged victim. The latter may be some months or years after the effluxion of the usual three year limitation period from the accrual of the cause of action. However it is rarely decades as it was in a recent case in the Queen’s Bench Division. In common with much of the extensive corpus of authority as to limitation, Keith Malcolm Lewin v Glaxo Operations Uk Ltd (Sued As Glaxosmithkline Unltd) [2016] EWHC 3331 (QB), turns on its own facts. It is however worthy of summary.

Here, upon hearing the trial of a preliminary issue on the subject, Mr Justice Goss found that the claimant’s claim was not statute-barred despite the claimant making complaint of treatment he received as long ago as 1973.

Some 44 years ago, the claimant underwent a diagnostic procedure during which Mydil was injected into his spine. It was held that the claimant’s date of knowledge arose when he was diagnosed as late as 2015 as suffering from post-Myodil adhesive arachnoiditis.

In the five or so years following the 1973 procedure, the claimant experienced persisting problems in his lumbar and cervical spine. This was investigated further in 1977 when it was considered that whilst the claimant may have had adhesive arachnoiditis, it could not be confirmed and further x-rays were unnecessary. The claimant’s problems continued during the 1990s, but it was not until 2007 when he developed severe left knee pain and thereafter other symptoms. An MRI scan in 20112 showed adhesions to his thoracic spine and the potential link between Myodil and the claimant’s condition was discussed. He underwent surgery in 2013, but it was not until March 2015 when a neurosurgeon concluded that the claimant suffered from post-Myodil adhesive arachnoiditis.

The claimant issued proceedings in October 2015 against the background of the fact that in the early 1990s group litigation had been pursued against the defendant in respect of Myodil in which settlements were agreed without any admission of liability. Over 4000 individuals had notified claims although, in the event, only 426 claims were proceeded with.

The Court was asked to determine the date upon which the claimant’s cause of action accrued; his knowledge for the purposes of section 14 of the Limitation Act 1980; and if the claim was statute-barred, whether the court’s discretion pursuant to section 33 of the same Act should be applied.

The court held that the cause of action accrued when the Myodil caused injury to the claimant, not the date it was injected. On the facts of this case this occurred around 2007.

The defendant argued that by the 1980s the claimant had constructive knowledge sufficient to commence time running (per section 14(3) of the 1980 Act): he knew by 1977 he had a serious back injury and that the possibility of arachnoidiis had been raised sufficient to prompt him to investigate. The claimant argued that no clear cause for his symptoms had been determined. This found favour with the Court which further held that even had the claimant drawn a link, it was not reasonable to have expected him to have investigated it further. It was held therefore that the claimant’s date of knowledge was when the neurosurgeon’s diagnosis in 2015.

Goss J went on to consider whether he would have allowed an extension of limitation in any event. He held that he would have done had it have been necessary on the grounds that the claimant had sustained a very serious injury and the main prejudice to the defendant would have been financial as the matters complained of had already been investigated.

Do You Think GSK Give A F*CK About Your Health And Well Being?…


X RAY Dye Scandal So Big That They Buried It..

Derek Morrison tells of how the toxic X-ray dye affected him, and prompted his pursuit for justice

EXCLUSIVE

DEREK Morrison lost control of his bladder, his bowel and became impotent after he was injected with the dye Myodil during an X-ray on his injured back in May 1977.

“The myelin sheath around the nerves had melted and fused and I never thought I’d move again,” says the former laboratory technician and salesman.

The radiologist who performed the myelogram on Derek left 21mm of the dye in his back and X-rays show some of it travelled to his brain.

He lost his job and sensation in his legs and nearly died before doctors performed 15 hours of microsurgery to save his life.

“They told me I was hypersensitive to the myelogram. I accepted it. At the end of the day you believe your doctors,” he said.

While he gradually recovered the ability to move relapses over the years saw Derek hospitalised numerous times to have weights put on his muscles and nerves to control the pain.

He was in a wheelchair on and off for four years before he was taught to walk again at a rehabilitation centre using secondary muscles in his legs.

His doctors prescribed methadone for 27 years to control the pain and at times it was so bad he was suicidal.

READ MORE: How medicine watchdog failed us over spinal X-ray dye

Derek Morrisson has a disease called Arachnoiditis. Picture: Mark Scott

It wasn’t until 1992 that Derek fully understood what had happened to him.

His UK based mother Iris had also been injured after a myelogram and chanced upon an article about a court case on “spider’s disease” caused by myelograms.

The article in the Daily Mirror in 1992 was about how UK patients suffering arachnoiditis after an x-ray were suing drug company GlaxoSmithKline.

It was a Eureka moment for the pair.

Derek’s mother became paralysed by the dye left in her body and died on the operating table when doctors tried to ease her condition.

It was then Derek began a 25 year fight for justice for arachnoiditis victims collecting thousands of pages of official documents relating to the dye and its use worldwide.

Derek Morrisson possesses this document from the Australian Department of Health, confirming Pantopaque dye was used. Picture: Supplied

These documents are now contained in bulging folders that line his living room and the search this year finally unearthed documents that show the TGB failed Australian patients.

In 2001 Derek began legal action against his radiologist, the hospital and the drug company but in the end the lawyers only went after the radiologist and Derek lost his case.

They told him he would not win a case against the drug company. “They talked me out of it even though 140 other Australians received an out of court settlement against the drug company.”

When Derek lost his case legal aid services across the country refused to take on any more cases.

“The government knew what they’d done and they shut it down knowing there were hundreds and thousands of cases coming behind me. They shut it down,” he said.

Derek Morrison, who has helped expose the problem has spent the last 10 years doing more research and has documents that implicate the failure of our medicine watchdog in the scandal. Picture: Gary Ramage

“There were millions of injections it would have cost billions to fix it, it was so big they just buried it,” he said.

Despite his work in amassing thousands of pages of documents that showed researchers, doctors and government regulators knew of the dangers of the dye for decades only three pieces of paper were ever used in his court case.

Derek tried and failed to stage a protest at the Sydney Olympics against the company Kodak which made the dye, Kodak was sponsoring the Olympics.

Derek blames the pain and disability he suffered as a result of the dye for the break up of his marriage and estrangement from his children.

“This dye was used in 107 countries. I believe 186,000 people were injected with Pantopaque in Australia, more when you take into account Myodil,” he says.

“The important thing is the TGB was not at the gate at the time protecting us,” he says.

“If the TGB had done their job hundreds of thousands of my fellow Australians like myself would not have been abused in this way,” Mr Morrison said.

“My life would have been very different if it did,” he says.

What Derek wants most is for the truth to be told.

“I want recognition this did happen, that the TGB truly failed us, ninety per cent of the sufferers don’t even know the link or what caused their problems,” he says.


4

Adhesive Arachnoiditis

Australians crippled and in chronic pain from dye used in toxic X-rays

EXCLUSIVE

Hundreds of thousands of Australians are crippled by pain, and some are paralysed and wheelchair-bound because the nation’s medicines watchdog failed to check the safety of a dye used in spine X-rays for 42 years.

Explosive new documents reveal for the first time how the government body charged with protecting the public approved the X-ray dye Pantopaque without ever obtaining the studies that showed it was toxic to animals and humans.

“There is no evidence that any animal or clinical studies were specifically requested, submitted or evaluated as part of the approval process,” the Regulatory Services Group at the Department of Health admitted in a letter to dye victim Derek Morrison in February.

The dye called iophendylate sold under the brand name Pantopaque and Myodil contains benzene, hydrochloric and sulphuric acids and is toxic enough to eat polystyrene cups and linoleum tiles.

Medical experts who gave evidence to a 2013 parliamentary inquiry have compared the case with the harm caused by tobacco giants and asbestos company James Hardie.

The phones went into meltdown when News Corporation in 2002 revealed the terrible impact of the dyes on Australians.

RELATED: The man who blew the whistle on the X-ray dye scandal

Derek Morrisson was injected with a dye for a medical X-ray that resulted in him contracting a disease called Arachnoiditis. Picture: Mark Scott

Medical tests in the 1940s on 15 dogs at Rochester University in the US showed the dye killed one dog, paralysed another and left most of the animals with inflammation of their nerve roots.

Ernie Hughes, one of several importers of the dye, says he never knew the dye was toxic and says it was approved by the FDA in the United States.

“If I’d known I wouldn’t have sold it and I would have demanded that Myodil be taken off the market too,” he said.

There is no suggestion that Mr Hughes knew or should have known about the dye’s risks, or that he was involved in any wrongdoing.

Pantopaque was mysteriously approved by the FDA on the February 22, 1944 after previously being refused a license weeks earlier due to it being ‘too toxic’ for human use.

In 1969 an application for a licence to sell a half strength version of the dye was withdrawn after a dog study found connective tissue lesions in half the animals, three dogs died, and another became partially paralysed. Rabbit studies show it produced malformed babies with bulging eyes and malformed heads. The full strength version remained on the market.

Ernie Hughes, who used to import the X-ray dye Pantopaque. Picture: Gary Ramage

The Health Department never checked these studies before approving the dye for use here.

Now the victims of the dye are demanding the department and the pharmaceutical companies that marketed the dye publicly admit it harmed thousands of patients.

They want their health and support costs covered, funding for research into the best way to alleviate their pain and fund a charity to support sufferers.

Their calls were backed by a parliamentary inquiry into the dye in 2013 which called on pharmaceutical company GSK to set up a charity for the victims, it has refused to do so.

“GSK considers it has acted responsibly at all times in regard to the supply of Myodil including appropriate testing and monitoring, updates to product information, fair engagement in all legal proceedings and participation in the roundtable process,” a spokeswoman for the company said.

“Taking all these points into consideration, GSK came to the view that it would not be appropriate to establish a charitable foundation,” she said.

Mr Morrison believes there has been a massive cover up by doctors, companies and governments who are ‘just waiting for us to die’.

“They couldn’t fix it, it was so big so they buried it,” he says.

A dye that was injected into people’s spines to get a better picture on an X-ray has left many patients in great pain and many disabled as it ate away their spine. Picture: Gary Ramage

Other victims have told News Corp they are furious that the medical records they need to take legal action over the dye “went missing”.

A spokesman for the Minister for Health and Aged Care, Sussan Ley, said they X-ray dyes were considered to be the best method available to diagnose serious conditions of the spine. at the time.

“We are all concerned for those who have the painful and debilitating side effects from the two medicines (Myodil and Pantopaque) which were used in patients from the 1960s until the 1970s,” he said.

“The concerns of patients who received these medications was the subject of a House of Representatives Standing Committee on Health Roundtable on Adhesive Arachnoiditis on 21 September 2012, he said.

“The committee report recommended that the sponsor of the medication, GlaxoSmithKline (GSK), should consider establishing a charitable foundation to assist sufferers of adhesive Arachnoiditis.

Jenny Carter from NSW is still suffering from being injected with the X-ray dye.

“I understand that GSK has compensated some patients, however, access to further assistance for other sufferers should be taken up with GSK.

“If there is any new evidence on this issue it should be brought forward and assessed,” he said..

Actress Jean Howell who co-starred with James Bond star Roger Moore in the television series The Saint was a famous victim of the dye.

Associate Professor Mal McLeod from the ANU’s Research School of Chemistry says the dye iophendylate was marketed under many names including the brands Myodil and Pantopaque in Australia “it’s the same compound,” he says.

In Australia the dye was injected into patient’s spines before X-rays called myelograms for 42 years, it was withdrawn from the market in 1987 and replaced by a new water based dye.

Radiologists knew iophendylate could cause arachnoiditis but say at the time it was the only way to get a decent X-ray image.

They admit they never warned their patients the painful condition called arachnoiditis was a potential side-effect.

Experts told a parliamentary inquiry the condition causes inflammation and fusion of the nerves and membranes of the spinal cord pain and delivers burning pain “like bolts of electricity”.

Victims also suffer loss of muscle function, paraplegia, incontinence, unpleasant sensations such as ants walking on the skin or having hot water poured on one’s legs. Many patients are wheelchair-bound.

Alan Wood from Queensland has also been left with side effects after his encounter with the dye.

In 2000 around 140 Australian victims of the dye received compensation from drug company GlaxoSmithKline which marketed the Myodil brand of the dye.

However, many victims are unaware the dye is the cause of their health problems and those who do have been unable to get compensation cases through the courts.

Now News Corp has learned when it had a chance to check the safety of the dye in the 1970s the Therapeutic Goods Branch (TGB) of the Department of Health failed to get the studies that should have raised alarm.

The Myodil brand of the dye was first used on humans in the 1940s well before Australia had a government body that checked the safety of medicines and medical products.

However in 1966 after the thalidomide scandal the Australian Government introduced the Therapeutic Goods Bill to regulate the sale of medicines and other therapeutic goods.

This meant that in 1972 when Myodil became contaminated and a Melbourne doctor began importing a US brand of the same dye called Pantopaque it was regarded as a new product and was covered by the new medicine regulations.

A letter from the Department of Health Therapeutic Substances Branch to Epworth Hospital in June 1972 explains:

“Pantopaque is regarded as a new therapeutic substance and has not been approved for general marketing in Australia.”

Glenda Nelson of Victoria says her life took a turn for the worse after she was injected with the dye.

The hospital was granted approval to use it in emergency cases only and as long as guidelines for experimental use were followed and chemistry and quality control data were provided.

In 1973 Nicholas Pharmaceuticals applied to the TGB for a licence to import Pantopaque into Australia.

Over the next two years various arms of the company were repeatedly asked by the TGB to supply studies on the safety and toxicology of the dye.

In February 1975 Cook Industries took over supplying the dye in Australia various Health department documents show.

The company was unable to obtain the studies from the US company Lafayette Pharmacal that marketed the dye.

Ernie Hughes the former managing director of Amyl Chemical Industries, the Australian branch of Nicholas that imported the dye and also former managing director of Cook Industries says he never knew about the studies in dogs that showed the dye was toxic.

“We only dealt with the commercial company selling Pantopaque, it had FDA approval,” he said.

There is no suggestion that Mr Hughes knew or should have known about the dye’s risks, or that he was involved in any wrongdoing.

He says medical practices at the time were very different to today and many radiographers as well as patients were injured by chemicals and X-ray dyes.

Gaye Hilder from South Australia also suffers from chronic pain every day.

“Who do you go to for compensation? … you can go back in history … here were an entirely different set of things done years ago,” he says.

Despite the fact the TGB did not get the safety and toxicity studies it allowed the various companies to import over 13,500 ampoules of the dye for use in hospitals and X-ray laboratories while the marketing permit was being considered.

And in June 1975 it inexplicably gave up asking for animal studies on the dyes, crossing the word “animal studies” off its request for information from the company.

The department should have been alert to adverse events because in 1969 the US FDA demanded the US supplier of the drug include warnings on the label that adverse reactions included “severe arachnoiditis producing headache, fever, meningitis, pain in the back and extremities and elevation of the white blood count”.

In 1977 our health department was asked by the US FDA to supply details of adverse reactions after it emerged the US company had never filed adverse reaction reports as required by law.

A departmental file note in 1971 shows the TGB had received “a number” of adverse reaction reports but was “not investigating these in the laboratory at this stage as an individual approach to each of these is not possible because our background in the testing of these drugs is rather limited”.

Later, in 1978 our National Biological Standards Laboratory had complaints from 8 doctors about Pantopaque.

And in June that year a Heidelberg Hospital patient died after being administered with the x-ray dye and the adverse drug reaction report says “maybe drug casualty possible”.

A copy of a document from Derek Morrisson from the Australian Department of Health, confirming the use of the X-ray due Pantopaque. Picture: Supplied

Despite this the dye was finally approved for marketing in 1979 without the TGB ever obtaining the animal and human studies it asked for to prove it was safe for use in humans.

“Pantopaque was assessed for safe use in humans as part of the assessment for its marketing approval, but as mentioned to Mr Morrison this did not include specific clinical studies or animal studies,” the department told News Corp.

“The sponsor did provide a list of over 100 publications on the use of the dye as part of the evaluation. There was also knowledge of the use of the dye over many years,” the Department said.

Flinders University Emeritus Professor Michael Sage. A radiologist, says he can’t believe the TGB approved Pantopaque for use in 1979 because he was warning them at that time it caused arachnoiditis.

“It was madness to approve it in the 1970s” he says.

“I struggled to get water based dyes approved in the 1970s because I was aware of arachnoditis,” he said.

“At the same time as they were approving Pantopaque we were asking them to approved a new water based dye because of arachnoiditis,” he said.

“They should never have approved Pantopaque in the 1970s, if they approved Pantopaque in the 1970s it was without taking on board people’s concerns about arachnoiditis,’ he said.

Radiologists used the oil based dyes Myodil and Pantopaque until the 1970s because there was no alternative way to get an image of the spine, he said.

“(They) used it because there was nothing better,” he said.

The dye ceased being marketed in Australia from 1987 but many thousands of patients who suffered its adverse effects have never been compensated and many may be unaware the dye caused their symptoms.


http://www.dailymail.co.uk/news/article-4024788/Disabled-solicitor-faces-rest-life-wheelchair-poisoned-doctors-child-suing-drugs-giant-Glaxo-millions-pounds-damages.html

Disabled solicitor who ‘faces the rest of his life in a wheelchair after being poisoned by doctors as a child’ is suing drugs giant Glaxo for millions of pounds in damages

  • Disabled Keith Lewin, 59, had suffered with back pain since his childhood 
  • Solicitor says Glaxo chemical injected into his back at 15 has led to life of pain
  • In 2013 surgeon found oily myodil still inside his spine, the High Court heard
  • Drugs giant GlaxoSmithKline says that Mr Lewin has left it far too late to sue
Keith Lewin, 59, had suffered with back pain since his childhood, and claims an agent injected into his spine as a child means he will spend the rest of his life in a wheelchair

Keith Lewin, 59, had suffered with back pain since his childhood, and claims an agent injected into his spine as a child means he will spend the rest of his life in a wheelchair

A disabled solicitor who faces the rest of his life in a wheelchair because he was inadvertently poisoned by doctors as a child is suing drugs giant GlaxoSmithKline for millions in damages, the High Court heard.

Keith Lewin, 59, suffered with back pain since his childhood but his health issues spiralled out of control in middle age and led to a devastating diagnosis in 2012.

He was told he had adhesive arachnoiditis, a rare spinal condition which causes debilitating pain and which has left Mr Lewin tetraplegic and confined to a wheelchair.

Mr Lewin, of Farington Moss, near Preston, claims that the blame lies in a procedure he underwent as a 15-year-old boy at Merseyside’s Whiston Hospital.

There, medics injected a ‘contrast agent’ called myodil into his spine so that it could be better viewed on an x-ray.

But the procedure did not reveal the source of Mr Lewin’s pain and instead led to his disability decades later, his legal team claims.

When he underwent an operation in 2013, a surgeon found the yellow oily myodil still inside his spine, the High Court heard.

Suing myodil’s maker and supplier GlaxoSmithKline for compensation, Mr Lewin claims it should have been withdrawn for use in diagnostic procedures years before it finally was in 1988.

‘He has suffered devastating injury,’ his barrister Simeon Maskrey QC told Mr Justice Goss.

‘And its attributability is clear to him and the surgeon who discovered myodil in his spine.’

Counter-claim: Drugs giant GlaxoSmithKline says that Mr Lewin has left it far too late to sue over something which happened so long ago

Counter-claim:

Drugs giant GlaxoSmithKline says that Mr Lewin has left it far too late to sue over something which happened so long ago

Myodil was used as a contrast medium in imaging of the back from the 1940s, allowing medics to better identify problems around the spine.

Mr Lewin’s lawyers claim it had not been sufficiently tested and, even if it could be used, Glaxo should have warned that it must only be in the most extreme cases.

A ‘better’ warning should also have been given about the need to remove the ‘unstable and toxic’ myodil immediately after x-rays, his lawyers claim.

The drugs giant denies all of the allegations and is trying to have Mr Lewin’s case thrown out.

Glaxo barrister, Jonathan Waite QC, argues that Mr Lewin has left it far too late to sue over something which happened so long ago.

He should have suspected by 1977 that he was suffering from the condition and took action to begin a claim before 1983, he said.

Mr Maskrey told the court that the first symptoms of adhesive arachnoiditis which Mr Lewin had were in 2007 when he felt a sudden excruciating pain while out walking.

But pointing to entries in the 20-year-old Mr Lewin’s diaries back in 1977, Mr Waite said the possibility of arachnoiditis was on his mind even then.

The young man, who was still being investigated for the cause of his back pain, had written of having ‘some symptoms’ of a condition which he spelled ‘racnoiditas’, said the barrister.

That must have come from either his orthopaedic surgeon or GP and should have been the moment when he began to investigate whether he could make a claim.

That he instead left it until he had a diagnosis three decades later meant his claim was ‘time-barred’ by the Limitation Act and should automatically fail.

‘Glaxo’s case is that the information about arachnoiditis imparted to him in 1977 was what should have prompted him, as a reasonable person, to be curious enough to start investigating what the cause of this might have been,’ said Mr Waite.

But Mr Maskrey said Mr Lewin had been told of a variety of possible causes of his pain in the mid and late 1970s, of which arachnoiditis was only one.

The pain he had suffered in those days was totally different from that which led to the discovery in 2012 that he had the condition, he continued.

Mr Maskrey said the earliest time in which Mr Lewin could have begun investigating a potential claim was 2007, but that he only had ‘actual knowledge’ of potential for damages in 2012.

That meant he was in time when he launched his claim and it should continue – unless Glaxo, with its ‘vast financial reserves’, decides to settle, he said.

Mr Lewin’s arachnoiditis, which causes inflammation of the membranes which surround the spinal cord, has left him severely disabled.

He suffers from debilitating pain and is confined to a motorised wheelchair both inside and outside his home.

He has had to make extensive adaptations to his home and his partner provides care. The condition is permanent and the prognosis is said to be ‘poor’, the court heard.

In 1995, Glaxo settled – without any admission of liability in relation to myodil – 426 claims which were due to go to court.

The judge reserved his decision on Glaxo’s bid to have Mr Lewin’s claim thrown out until a later date.


Man Sues Glaxo Over Horrific Spinal Injury From Their Dodgy Dye Myodil…


https://www.leighday.co.uk/News/News-2016/December-2016/Solicitors-legal-challenge-against-GlaxoSmithKline

 

Solicitor’s legal challenge against GlaxoSmithKline can continue

Myodil spine injury claim can proceed after High Court limitation ruling

Keith Lewin

22 December 2016

A 59 year old solicitor, Keith Lewin, has succeeded in the latest stage of his seven figure legal claim against Glaxo Operations UK Limited (part of the corporate structure of the pharmaceutical company GlaxoSmithKline) who he believes is responsible for the illness that has left him a wheelchair user.

Mr Lewin is represented by product liability solicitors Jill Paterson and Thomas Jervis.  You can read a full copy of the Lewin judgment.

Mr Lewin is suing Glaxo Operations UK Limited (part of the corporate structure of GlaxoSmithKline) for a seven figure sum arising out of his exposure to Myodil, an oil based contrast medium, which was injected into his spine in 1973 when he underwent a diagnostic Myelogram procedure to investigate back pain as a 15 year old.

It is alleged that his exposure to Myodil caused him to develop the spinal condition known as adhesive arachnoiditis which is a serious inflammatory condition of the spinal cord.  Mr Lewin is now severely, permanently disabled. He requires the use of a motorised wheelchair in order to mobilise.

Mr Lewin alleges that the Defendant (the successor of Glaxo Laboratories Limited) was negligent in respect of the manufacture, supply and use of Myodil.

Myodil was used as an oil-based contrast agent in the imaging of spines of patients with back pain in the United Kingdom from the 1940s until its product licence expired in 1987.

There was previous UK Group Litigation brought by a large number of other Claimants (eventually 426) in negligence against Glaxo in the early 1990s arising out of their alleged exposure to Myodil. That litigation settled in July 1995 for the sum of £7 million without an admission of liability.

Glaxo argued that Mr Lewin’s claim was time barred and should not be allowed to continue.  They say that he should have been put on a train of enquiry in the late 1970s or early 1990s which would have led him to make a legal claim much earlier.

Mr Lewin argued that it was not until 2012 that he was diagnosed with adhesive arachnoiditis before he underwent exploratory spinal surgery known as a laminectomy.  It was submitted that even if the Court were to deem that his claim had been brought outside the three year statutory limitation period, it would still be equitable to allow the claim to proceed.

Mr Justice Goss handed down his judgment on 20 December 2016 in the High Court ruling that Mr Lewin’s claim was brought within the legal time limit, and that he would allow the claim to continue.

Leigh Day product liability solicitor Jill Paterson said:

“My client is very pleased that his spinal injury claim is allowed to proceed. He suffers with constant debilitating pain and has to use a wheelchair. His life has been significantly affected”.

Information was correct at time of publishing. See terms and conditions for further details.

Myodil Australia: Glaxo Wellcome faces significant damages claim over xray dye


http://www.afr.com/business/legal/glaxo-wellcome-faces-significant-damages-claim-over-xray-dye-20150705-ghzn35

Glaxo Wellcome faces significant damages claim over xray dye

Glaxo Wellcome faces significant damages claim over xray dye

The group of patients argue Glaxo Australia continued using Myodil despite that it knew or should of known about the risks which had been published in medical reports since 1956.
The group of patients argue Glaxo Australia continued using Myodil despite that it knew or should of known about the risks which had been published in medical reports since 1956. Reuters
by Marianna PapadakisPharmaceutical and chemical manufacturer Glaxo Wellcome Australia is facing legal action brought by 19 people for personal injuries arising from a dye used in a medical procedure.

The 19 patients are seeking damages for their contraction of a rare inflammatory condition called adhesive arachnoiditis because of the alleged use of the company’s oil-based dye Myodil during a myelogram.

A myelogram is a spinal x-ray that involves using a special contrasting dye that is injected into the cerebrospinal fluid of the spinal canal to enable the spinal cord and nerve roots to be examined.

Adhesive arachnoiditis is a painful and debilitating condition that results from the long-term scarring of the arachnoid, one of the membranes that surrounds and protects the nerves of the spinal cord.

In some very severe cases it can cause paralysis, bladder and bowel dysfunction and impaired sexual function.

The group of patients argue Glaxo Australia continued using Myodil despite that it knew or should have known about the risks, which had been published in medical reports since 1956.

They also claim Glaxo failed to warn patients and healthcare professionals about the risks of using the dye.

Glaxo Wellcome Australia is now known as GlaxoSmithKline Australia. The company manufactures pharmaceuticals, antibiotics, surgical equipment and laboratory chemicals.

A spokeswoman for the company said it considers it acted responsibly at all times in regard to the supply of Myodil including appropriate testing and monitoring, and updates to product information.

Statutory time limit

NSW Supreme Court judge Peter Garling ruled on Friday that a hearing on whether some of the claimants were outside the statutory time limit to bring a claim should be held ahead of a full trial.

According to the judgment twelve of the claimants were based in NSW, four in Queensland, two in Tasmania and one in Western Australia and all undertook the procedure between 30 to 43 years ago and were diagnosed between 1976 and 2012.

Glaxo Australia argues that if the patients did contract adhesive arachnoiditis it could have resulted from using another oil-based contrast medium called Pantopaque, which it did not manufacture but was used in Australian hospitals and radiology practices at the time.

The company also claims it could be prejudiced because of the unavailability of medical records and evidence for many of the patients as well as the inability to join any other medical practitioners as cross-defendants.

It contends it does not owe the patients a duty or care and that it gave particular warnings on product information leaflets and at different points in time.

Plaintiffs’ evidence

The company is paying for the plaintiffs’ evidence to be taken either in or close to their homes as many argue they are incapacitated and are not able to attend two hearings.

One patient has since died and the others are between 57 years to 86 years and largely confined to their homes.

Justice Garling said there were significant issues with respect to plaintiffs who received their diagnoses at a time well prior to the commencement of proceedings.

Remembering GSK’s Myodil Again: “This has been going on for years and years”


60, 000 people affected by a GSK product, Myodil, and GSK do nothing for their suffering!

100, 000 excess heart attacks in the US alone because of GSK’s Avandia, and GSK do nothing to help these people and their families. At least in the US- there is some chance of legal success- in the UK- GSK do everything in their power to squash claims against them…

Hundreds of thousands of lives ruined from Seroxat/Paxil, and in the UK, at least- nothing is done to bring GSK to book over these grave abuses of human rights. We are talking about dead children here! Due to Seroxat’s suicidal side effects! That could be anyone’s son, daughter, child, sister, brother!

GSK… Once again… You are an utter disgrace to humanity.

Your Motto of “Do more, feel better and live longer” must be a sick bloody joke!

Shame on you..


http://www.canberratimes.com.au/act-news/answers-may-give-some-rest-20130302-2fdlg.html

Answers may give some rest

Date
March 3, 2013
  • Read later
Joern Hagemann showing the xray where an oil-based contrast media used in myelography called Myodil.Joern Hagemann showing the xray where an oil-based contrast media used in myelography called Myodil. Photo: Jay Cronan

THE simplest movements – walking, sitting and even lying down – cause Joern Hagemann extreme pain. In 1978 his spine was injected with Myodil after a construction accident. But the dye used in X-ray procedures has been linked to adhesive arachnoiditis, a deteriorating and debilitating condition that leaves sufferers crippled with terrible pain, paralysed and incontinent.

Mr Hagemann considers himself lucky. He is able to walk around his Spence home with the help of his wife, Ursula, and a cane. He does not want pity, he wants answers. Why the oil-based ink was considered safe for internal use when doctors were warned to be careful about spilling it as it corroded rubber; and why it was used until 1987.

He said the February findings of a round table on adhesive arachnoiditis by the standing committee on health and ageing left many questions unanswered.

The committee’s first recommendation was for GlaxoSmithKline, the company that marketed the product for 42 years, to consider establishing a charitable foundation to assist the sufferers of adhesive arachnoiditis.

 

”I want it investigated further. I tried through the round table but they sugar-coated it,” Mr Hagemann said.

”I wanted the government to finally sort out what’s going on with the drug company. That’s not asking much when there are more than 60,000 people involved.”

He said a suggestion to start a charitable foundation was not enough for a dark incident in Australian medical care that Throsby MP Jennie George called a ”conspiracy of silence”.

”We were never told it was dangerous. We were never asked if we wanted it. This is the whole point.”

In a statement a spokeswoman from GlaxoSmithKline said the company acted responsibly in relation to the supply of Myodil.

”We are currently considering the information within the report, including recommendation one, which encourages GSK to establish a charitable foundation to assist sufferers of adhesive arachnoiditis,” she said.

But Mr Hagemann wants a real investigation.

”This has been going on for years and years and years.”

Read more: http://www.canberratimes.com.au/act-news/answers-may-give-some-rest-20130302-2fdlg.html#ixzz2NpMeLxQe

Living with the pain of GSK’s Myodil


As Deputy Chair of the House of Representatives Standing Committee on Health and Ageing, I rise to respond to the chair’s statement on the report Living with the pain of adhesive arachnoiditis: report on the roundtable into adhesive arachnoiditis. I start with the following statement:

Our guiding principles are to focus on patient needs, respect people, communicate honestly and act with integrity. We are bound by a promise to keep our customers at the heart of everything we do. We do this work in partnership with Government, industry, the community and our peak industry association,

Any suffers of adhesive arachnoiditis will recognise this motherhood statement taken from the GlaxoSmithKline website. GSK is the company that released the Myodil and Pantopaque products into the medical world, which are a cause of the condition known as adhesive arachnoiditis, described in the report as a painful condition. We heard the chair say in her statement that this is a horrific condition.

The report states that the committee very much appreciates the contributions of all participants to its inquiry. The roundtable made clear to the committee how debilitating adhesive arachnoiditis can be to sufferers. The committee very much sympathises with and hopes that the recommendations of the report will help to improve the quality of life for sufferers and their families and carers. I particularly mention Mr Max Scott from my electorate of Swan, who first brought to this terrible condition to my attention. I also thank Mr Joern Hagemann and his daughter and carer, Mrs Erika Zorzit, who both came to visit me about Mr Hagemann’s condition. Their visit gave me the extra impetus to cajole, urge and convince the Standing Committee on Health and Ageing to commit to a roundtable and I thank my fellow committee members for their support in agreeing to the roundtable.

In particular I thank Steve Georganas, the previous chair, and Jill Hall, the current chair, both of whom played their part in getting this roundtable up. I thank the secretariat for their work on this difficult report as I felt there was a level of trepidation in dealing with this subject due to the long litigious history of the subject and the ongoing litigation. Thanks must also be given to the previous member for Throsby Jennie George for tackling this issue back in the early 2000s with the support of Jill Hall.

I also mention Mr Jonathan Martin from my office who spent a considerable amount of time dealing with sufferers and providing me with valuable research. His efforts should not go unnoticed by the people who read this report. During my time involved with the forgotten Australians apology more than three years ago, the comment that the Leader of the Opposition at that time, Malcolm Turnbull, made in his speech when he said, ‘We believe you,’ was, for many people, a significant moment. I think the same significance could be taken by arachnoiditis sufferers from the comments made by Professor Michael Sage, a radiologist, when he stated:

I believe that the most common cause of chronic arachnoiditis is Myodil, and most people have been suffering for 40 years. … These people have suffered, mainly because we were using a dye, Myodil, with no alternative. … there was a gradual recognition—with poor literature, I might say—that there was a problem. A needle was introduced to allow us to suck it out; the problem was that it was often impossible to suck it all out anyway. The bottom line was that, if there was some alternative, we should not have been putting it in. I was very concerned about this.

The report’s recommendation 1 goes back to the first part of my statement that was taken from the GSK website. This recommendation’s first paragraph states:

In the context of corporate social responsibility the Committee encourages GlaxoSmithKline to consider establishing a charitable foundation to assist sufferers of adhesive arachnoiditis.

This is a decision that only GSK can make. However, if we are to believe all the motherhood and community caring messages stated on their websites around the world, we can only hope that they honour these statements. If they do not act, their response to this recommendation will give us a true indication of GSK’s real community concern. In the report there is a comment that states there is an acceptable failure rate of 10 per cent for people who contract arachnoiditis from a myelography. I ask: would that be an acceptable failure rate for a motor vehicle manufacturer? The clear answer is no. My experience with manufacturing is that a one per cent failure rate is acceptable before they have a recall. I encourage people to read this report and again thank all the people who were able to finally have this debilitating condition brought to public awareness through this report. I commend this report to the House.

GlaxoSmithKline told to set up charity for thousands of Australians left crippled by X-ray dye


http://www.news.com.au/national/glaxosmithkline-told-to-set-up-charity-for-thousands-of-australians-left-crippled-by-x-ray-dye/story-fncynjr2-1226579441171

GlaxoSmithKline told to set up charity for thousands of Australians left crippled by X-ray dye

THEY are the forgotten Australians – 60,000 victims of a devastating medical practice that has left them crippled with pain, paralysed and incontinent.

This week they enjoyed a rare ray of light when Federal Parliament said they deserved the help and support of the drug company linked to their suffering.

GlaxoSmithKline (GSK), which for 42 years marketed a dye used in an X-ray procedure connected to their pain, has been told to set up a charitable foundation to help.

However, while the pharmaceutical giant told News Limited it was “considering” the parliamentary report’s recommendations, it has so far not yet committed to providing any assistance.

Medical experts who gave evidence to a parliamentary inquiry have compared the case to the harm caused by tobacco giants and asbestos company James Hardie.

“I sit back and think: cigarettes, mesothelioma – I go through it all. These people have suffered mainly because they were using a dye, Myodil, with no alternative,” Professor Michael Sage, past president of the Royal Australian and New Zealand College of radiologists told the roundtable.

Between 1945 and 1987 tens of thousands of Australians were injected with a dye during an X-ray procedure called a myelogram that at the time was the only way for doctors to see the spine clearly before surgery.

The federal government, state health authorities and doctors sanctioned the use of the chemical even though they knew evidence had emerged in medical journals as early as the 1950s that it was linked to a condition called arachnoiditis that causes burning back, neck and leg pain.

The condition is caused by the inflammation and fusion of the nerves and membranes of the spinal cord and is estimated to have affected around one per cent of patients who had the procedure.

Pain expert Professor Michael Cousins told the parliamentary roundtable victims suffered pain that was burning and “like bolts of electricity” – just moving to the end of the bed can be enough to trigger a paroxysm of pain.

Patients can also experience loss of muscle function, paraplegia, incontinence, unpleasant sensations such as ants walking on the skin or having hot water poured on one’s legs. Many are wheelchair-bound.

Arachnoiditis sufferer Maxwell Scott told the committee he now existed on an electric wheelchair and a bed, transferring from one to the other by means of a slide board.

News Limited first exposed the issue of spinal injections in 2002 and it was raised in federal parliament but the plight of the victims was ignored by the government even though its own medical regulator had evaluated the dye and approved it for general marketing.

Liberal MP Steve Irons pushed for a parliamentary investigation after being approached by a constituent and says it’s time for GSK to “act like a good corporate citizen” and set up a charitable foundation to help the victims.

“I guess if you look at GSK’s website they talk about openness and transparency, but I felt they hadn’t taken responsibility for this and assisted the people who were affected,” he said.

“Where you take no responsibility it smacks of the tobacco industry’s approach to smoking and cancer,” he told News Limited.

The parliamentary roundtable said it had no power to order GSK to pay the victims’ compensation – that was a matter for the courts.

In 2000 GSK faced a class action from 140 Australian victims of the dye, the case was settled out of court and the payouts were confidential .

In 1995, 3,600 UK victims sued GSK but only 426 received an average payout of 16,000 British pounds in an out of court settlement.

In a statement this week GSK said it “had the utmost sympathy for the people who have been, and are, afflicted by arachnoiditis” and believed it had “acted responsibly at all times in relation to the supply of myodil”.

“Arachnoiditis is a complex condition that may be caused by a number of conditions such as spinal infections, surgery and trauma,” the company said.

Many victims can’t get a diagnosis from their doctors, who also fear legal action, and many have their legal options complicated because they had surgery after a myelogram.

There is currently another compensation case underway in Australia but the president of victim support group The Australian Arachnoiditis Sufferers Association NSW, Maureen McLean, says lawyers have warned victims they “could lose their homes if they sue the company unsuccessfully”.

“It just doesn’t seem fair,” she said.

John Hagerman who had a myelogram in the 1970s is greatly disappointed at the parliamentary roundtable’s findings.

”There are thousands of Australians suffering like hell and no direct course to have it properly investigated,” he said.

He wants someone to be made legally responsible for the suffering cause by the dye.

ARACHNOIDITIS: KEY FACTS

  • 1945-87: oil based dyes Myodil and Pantopaque injected for use in spinal x-rays
  • 1956: article in The Lancet links Myodil to persistent pain in head, neck, back and legs
  • 1960s: two articles in journal Radiology link the dye to arachnoiditis and call for it to be removed after x-ray
  • 1969: US officials ask producers of Pantopaque to state on the product it should be removed after x-ray
  • 1970s: UK doctors decide to remove Myodil after the x-ray because of concerns
  • 1971: GSK inserts on its product information advice for Myodil that “occasionally arachnoiditis has been reported”.
  • 1973: GSK changes product information to “emphasise the importance of removing as much Myodil as possible at the time of investigation”
  • 1979: federal Department of Health approves an application to register Pantopaque for general use in Australia
  • 1980s: Pantopaque and Myodil (1987) withdrawn from sale
  • 1995: 3,600 UK patients seek compensation from GSK in relation to Myodil, 426 get a small settlement.
  • 2000: GSK reaches out court settlement with around 140 Australian claims in relation to Myodil

OTHER GSK LEGAL AND REGULATORY BATTLES

  • 2003: GSK drug Seroxat, a common anti-depressant, was banned for use in children aged under 18 in the UK because of concerns it triggered suicides
  • 2010: The licence for GSK’s diabetes drug Avandia was revoked in Europe because of evidence that it could cause heart failure and heart attacks.
  • 2011: GSK settled a US lawsuit over Avandia but continue to fight compensation claims over the drug in Britain. (Avandia is still sold in Australia)
  • 2012: GSK was hit by a $3 billion penalty in the US after revelations it handed out cash, rock concert tickets, pheasant hunting trips to induce doctors to prescribe medicines for unapproved conditions.

Remembering The Victims of Glaxo’s “Myodil”


“Strapped to a NHS x-ray table, a hypodermic needle thrust in to your central nervous system, tortured, poisoned with Myodil (Pantopaque), then left maimed in agonizing pain to slowly die?”

SATURDAY, AUGUST 27, 2011

January 2013, important new website in association with the Myodil Action Group, “Myodil Victims: Worldwide Register” (Link)Stop Press, September 2012, Good friend Dr. Charles V. Burton M.D. F.A.C.S sent Ursula Coxhead an article, “Mengele in America: Human Experimentation and the Walter Reed Connection,” which he wrote for the Journal: Ethics in Biology; Engineering and Medicine.  (Link)July 2012, Dr. Burton becomes President Elect of the Association for Medical Ethics (Link)In Dr. Burton’s letter to Ursula Coxhead dated 8/11/2011 he states, “all Myodil Myelogram’s produced a toxic chemical meningitis to some degree, which then progressed to a secondary condition called Adhesive Arachnoiditis which is diffuse and accounts for the greatest number of cases of clinically significant Adhesive Arachnoiditis, and easily distinguishable from focal (local) Arachnoiditis caused by trauma or surgery which leaves the patient with no discernible symptoms.” A copy is on page fifteen of this blog.

For even more historical document information please visit the Myodil Action Group website. The Myodil Action Group was solely responsible for the inception of the House of Commons Myodil All Party Group and is the only group working with it and is demanding a public inquiry. If you want justice there are three things you should do. Please join the Myodil Action Group (MAG), chaired by Ursula Coxhead. If you live in the UK you should contact your MP explaining you are a sufferer of Myodil induced Adhesive Arachnoiditis and you want him or her to join the House Of Commons All Party Myodil Action Group you should also sign their e-petition to help them fight for a public inquiry, recognition, and compensation.

There is a conspiracy to hide this huge medical injury scandal. They ignored the warnings Myodil was unsafe but through willful ignorance or willful negligence they continued to use it, which means it is actually unlawful “criminal” injury, manslaughter or murder, the evidence is overwhelming. In the UK there are no statute of limitations on criminal offences.

The spinal cord is a pure environment which should not be insulted with needles and chemicals. If you went in to hospital with back ache and underwent a Myodil Myelogram it doesn’t matter if they found anything wrong with your spine or not, you came out with toxic chemical meningitis (a separate devastating injury far worse than any prior injury you may or may not have had) leading to diffuse Adhesive Arachnoiditis. These conditions are incurable and un-treatable, causing intractable pain and organ dysfunction/failure, both of these problems lead to death however they cover it up by stating death is caused by natural causes from organ failure.

_______________________________________________

http://www.gsk.com.au/media-centre_detail.aspx?view=547

Press Releases

21 Sep 2012 – Public roundtable Arachnoiditis

GlaxoSmithKline (GSK) provided information to the Standing Committee on Health and Ageing’s public roundtable on Arachnoiditis through an ‘in- camera’ basis.

GSK has the utmost sympathy for the people who have been, and are, afflicted by arachnoiditis. Arachnoiditis is a complex condition that may be caused by a number of conditions such as spinal infections, surgery and trauma.

Myodil was an injectable dye used by doctors as a contrast medium for x-ray purposes in myelography and supplied by Glaxo from 1950.

Although a causal link between Myodil and arachnoiditis was not established, when the company became aware of a possible association, it included a precautionary warning in the Myodil product information sheet that there was a possible risk of arachnoiditis from the use of this medicine.

Myodil was not withdrawn from the market in Australia but discontinued in 1987 when newer diagnostic radiographic techniques became available.

All pharmaceutical products have side-effects, which doctors have to take into account by weighing them against the benefit to be gained by using the products.

In Australia, a court action around Myodil was launched against Glaxo and in 1999 Glaxo reached a settlement with claimants. The settlement was without admission of guilt. GSK is not at liberty to divulge the details of the settlement as these are confidential.

GSK believes that it acted responsibly at all times in relation to the supply of Myodil. Glaxo supplied this diagnostic product with the information available at that time to meet the needs of a very knowledgeable and specialist medical profession for many years, until it was superseded by newer products and technology.

GlaxoSmithKline is a global research-based pharmaceutical and healthcare company with a proud history in Australia dating back to 1886. Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

_____________________________________

https://sites.google.com/site/myodilvictims/

Worldwide millions of people underwent Myodil Myelogram’s, five million in America, a million in the UK etc. only Russia and Sweden wouldn’t use it because they thought it was dangerous. This medical injury is massive, the biggest ever, bigger than thalidomide.  As soon as you mention the phrase Myodil induced Adhesive Arachnoiditis, doctors become embroiled with psychological problems. If you have been lucky enough to have a scan through the NHS, they have purposely been done incorrectly so that it doesn’t show Adhesive Arachnoiditis (this happened to me). They do not want to admit they have been injuring/killing millions of people. So the medical profession have been lying through their teeth conspiring for decades to cover it up by ignoring it or telling you that you don’t have it.Extremely lucrative jobs and reputations are at stake, not to mention the massive possible compensation cost. So they are all working together protecting each other and to contain it to a minimum (aiding and abetting, which is unlawful). Nobody wants to expose Glaxo for selling a dangerous product that has been killing millions of people, once again lucrative jobs and reputations are at stake. Because this medical injury is so big in numbers and so damaging to the human body, the medical profession have had good cause to cover it up, because of this the media haven’t been able to understand just how serious it is.

This medical injury is iatrogenic which means the medical profession and Glaxo caused it, and because they caused it they don’t want to admit to it so you are blacklisted and can’t get a diagnosis or treatment, making you a sufferer of iatrogenic neglect which is cruel and shows how ruthless the medical profession is in guarding themselves over medical injury claims.

It’s not just Myodil Myelogram’s they have been injuring people with, it’s badly performed epidural’s as well.

Posted by eddy at 3:17 PM No comments:

Myodil
Victims

Worldwide Register


dralisonbarrett

the ecosystem approach to obgyn

My Life in my 60's

Finding joy in my 60's

The Vile Mint

Poetry, Short Stories and Violent Ideas

POSITIVELY HERE

"HAVE NO FEAR OF PERFECTION, YOU'LL NEVER REACH IT" - Salvador Dali

Rebel City Writers

A radical perspective on local, national and international issues from the pens of a few disgruntled agitators!

Critical Dispatches

Reports from my somewhat unusual life

~ L to the Aura ~

sustainability. compassion. inspiration.

Heroes Not Zombies

becoming not being.......

DES Daughter Network

Because Social Media increases Awareness and brings the DES Community Together

recovery network: Toronto

people can and do recover from what is sometimes called "mental illness"

Deidra Alexander's Blog

I have people to kill, lives to ruin, plagues to bring, and worlds to destroy. I am not the Angel of Death. I'm a fiction writer.

%d bloggers like this: